Neurology
SMA Treatment Finally Reaches the Muscle
FDA approval of ISEMBYLD adds the first muscle-targeted treatment to SMA care. It does not replace SMN-directed therapy; it exposes what patients may still lose even after the genetic pathway is treated.
Huntington’s Needs More Than a Better Curve
Duchenne’s Accelerated Approval Faces Its Test
Neurology Is Trying to Stop Nerves Dying, Not Just Treat What Is Left
MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.
MS Does Not End at the Clinic Door. It Follows People Into Work, Money and Relationships.
For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door
A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.
When the Test Says Normal but the Pain Does Not
When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases